Pulmonary Fibrosis Stem Cell Therapy in Istanbul, Turkey

Stem cell therapy for pulmonary fibrosis and interstitial lung disease. MSC treatments target the TGF-β1/Smad fibrotic pathway, break down existing lung scarring through MMP activation, and promote alveolar epithelial regeneration. Evidence-based regenerative approach for IPF, NSIP, and post-COVID lung fibrosis.

About Pulmonary Fibrosis Stem Cell Therapy in Istanbul

Stem cell therapy for pulmonary fibrosis at StemCell Longevita in Istanbul targets the fibrotic pathways destroying lung tissue, promoting alveolar repair and improving respiratory function. Our MSC treatments offer hope for patients with idiopathic pulmonary fibrosis (IPF), post-COVID lung fibrosis, and other interstitial lung diseases.

How Stem Cell Therapy Works for This Condition

Pulmonary fibrosis involves progressive scarring of lung tissue, driven by overactive fibrotic pathways (TGF-β1/Smad signaling). MSCs inhibit these fibrotic pathways, break down existing scar tissue through MMP (matrix metalloproteinase) activation, regenerate damaged alveolar epithelium, and reduce the chronic inflammation perpetuating fibrosis. This multi-mechanism approach addresses both the cause and consequences of lung scarring.

Who Is a Candidate?

Patients with IPF, NSIP, connective tissue disease-related ILD, post-COVID pulmonary fibrosis, and other interstitial lung diseases. Most beneficial in mild-to-moderate disease where functional lung tissue remains. Patients experiencing progressive decline despite antifibrotic therapy (pirfenidone, nintedanib) may benefit from MSC co-therapy.

Treatment Process at StemCell Longevita

After review of HRCT imaging, pulmonary function tests, and 6-minute walk test results, treatment involves IV MSC infusion. The pulmonary capillary bed captures a significant proportion of IV-infused cells, ensuring targeted delivery to damaged lung tissue.

Expected Results & Recovery

Stabilized or improved lung function (FVC), improved exercise capacity, reduced oxygen supplementation needs, and enhanced quality of life within 3-6 months. HRCT may show reduced ground glass opacities and honeycomb changes in some patients.

Why Choose Turkey for Treatment?

Istanbul's pulmonology centers provide advanced HRCT imaging and pulmonary function testing. Our anti-fibrotic MSC protocols offer an alternative at 60-80% lower cost than Western specialty centers.

Cost of Treatment

Pulmonary fibrosis stem cell therapy from €7,500, including pulmonary assessment, MSC infusion, hotel, transfers, and 12-month respiratory follow-up.

Related treatments: Diabetes Stem Cell Therapy | Hepatitis Stem Cell Therapy | Liver Disease Stem Cell Therapy | COPD Stem Cell Therapy | Kidney Disease Stem Cell Therapy

Frequently Asked Questions About Pulmonary Fibrosis Stem Cell Therapy

Can stem cell therapy help with pulmonary fibrosis?

Clinical research shows that mesenchymal stem cells (MSCs) can reduce lung inflammation and fibrosis progression. MSCs secrete anti-fibrotic mediators including hepatocyte growth factor (HGF) and prostaglandin E2 (PGE2) that counteract the excessive collagen deposition characteristic of pulmonary fibrosis. Multiple clinical trials report improvements in pulmonary function tests, 6-minute walk distance, and quality of life scores.

What types of pulmonary fibrosis can be treated with stem cells?

MSC therapy has been studied for various forms of pulmonary fibrosis including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), radiation-induced pulmonary fibrosis, and fibrosis secondary to autoimmune conditions. The anti-fibrotic and immunomodulatory properties of MSCs make them applicable across different etiologies of lung fibrosis.

How do stem cells reduce lung scarring?

MSCs combat pulmonary fibrosis through multiple mechanisms: they inhibit myofibroblast differentiation (the cells that produce excess scar tissue), secrete matrix metalloproteinases (MMPs) that break down existing fibrotic tissue, reduce TGF-β1 signaling that drives fibrosis, and promote the regeneration of healthy alveolar epithelial cells. This multi-targeted approach addresses both the cause and the consequences of lung fibrosis.